Ginwa Enterprise Group Inc (600080) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Ginwa Enterprise Group Inc (600080) has a cash flow conversion efficiency ratio of 0.019x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥29.81 Million ≈ $4.36 Million USD) by net assets (CN¥1.58 Billion ≈ $231.66 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See 600080 equity financing ratio to measure how much of total assets are equity-financed.
Ginwa Enterprise Group Inc - Cash Flow Conversion Efficiency Trend (1998–2025)
This chart illustrates how Ginwa Enterprise Group Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Ginwa Enterprise Group Inc (600080) cash flow quality to evaluate the quality of earnings relative to operating cash generation.
Ginwa Enterprise Group Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Ginwa Enterprise Group Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Beijing Bohui Science & Technology Co Ltd
SHG:688004
|
-0.017x |
|
Zhangjiagang Haiguo New Energy Equipment Manufacturing Co. Ltd.
SHE:301063
|
N/A |
|
Praemium Ltd
AU:PPS
|
0.056x |
|
Eaton Vance National Municipal Opportunities Closed Fund
NYSE:EOT
|
0.020x |
|
Eledon Pharmaceuticals Inc
NASDAQ:ELDN
|
-0.103x |
|
Eagle Point Income Company Inc
NYSE:EIC
|
0.022x |
|
Calamos LongShort Equity & Dynamic Income Trust
NASDAQ:CPZ
|
0.125x |
|
Putnam Managed Municipal Income Closed Fund
NYSE:PMM
|
0.036x |
Annual Cash Flow Conversion Efficiency for Ginwa Enterprise Group Inc (1998–2025)
The table below shows the annual cash flow conversion efficiency of Ginwa Enterprise Group Inc from 1998 to 2025. For the full company profile with market capitalisation and key ratios, see 600080 market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CN¥1.56 Billion ≈ $228.04 Million |
CN¥24.77 Million ≈ $3.62 Million |
0.016x | +128.23% |
| 2024-12-31 | CN¥1.56 Billion ≈ $228.20 Million |
CN¥10.86 Million ≈ $1.59 Million |
0.007x | -81.16% |
| 2023-12-31 | CN¥1.64 Billion ≈ $239.75 Million |
CN¥60.55 Million ≈ $8.86 Million |
0.037x | +18.34% |
| 2022-12-31 | CN¥1.68 Billion ≈ $246.39 Million |
CN¥52.58 Million ≈ $7.69 Million |
0.031x | +69.04% |
| 2021-12-31 | CN¥1.66 Billion ≈ $242.36 Million |
CN¥30.59 Million ≈ $4.48 Million |
0.018x | -31.70% |
| 2020-12-31 | CN¥1.72 Billion ≈ $251.89 Million |
CN¥46.56 Million ≈ $6.81 Million |
0.027x | -58.36% |
| 2019-12-31 | CN¥1.72 Billion ≈ $251.06 Million |
CN¥111.45 Million ≈ $16.31 Million |
0.065x | +294.35% |
| 2018-12-31 | CN¥1.77 Billion ≈ $259.22 Million |
CN¥29.18 Million ≈ $4.27 Million |
0.016x | -57.02% |
| 2017-12-31 | CN¥1.12 Billion ≈ $163.66 Million |
CN¥42.87 Million ≈ $6.27 Million |
0.038x | -1.25% |
| 2016-12-31 | CN¥1.07 Billion ≈ $157.13 Million |
CN¥41.68 Million ≈ $6.10 Million |
0.039x | +33.85% |
| 2015-12-31 | CN¥1.05 Billion ≈ $153.06 Million |
CN¥30.33 Million ≈ $4.44 Million |
0.029x | -13.83% |
| 2014-12-31 | CN¥1.02 Billion ≈ $149.29 Million |
CN¥34.33 Million ≈ $5.02 Million |
0.034x | -23.57% |
| 2013-12-31 | CN¥998.35 Million ≈ $146.09 Million |
CN¥43.96 Million ≈ $6.43 Million |
0.044x | +132.20% |
| 2012-12-31 | CN¥962.22 Million ≈ $140.80 Million |
CN¥18.25 Million ≈ $2.67 Million |
0.019x | -80.86% |
| 2011-12-31 | CN¥918.45 Million ≈ $134.40 Million |
CN¥91.02 Million ≈ $13.32 Million |
0.099x | +76.26% |
| 2010-12-31 | CN¥724.97 Million ≈ $106.09 Million |
CN¥40.76 Million ≈ $5.96 Million |
0.056x | +3.91% |
| 2009-12-31 | CN¥691.57 Million ≈ $101.20 Million |
CN¥37.42 Million ≈ $5.48 Million |
0.054x | -69.61% |
| 2008-12-31 | CN¥696.22 Million ≈ $101.88 Million |
CN¥123.96 Million ≈ $18.14 Million |
0.178x | +1452.87% |
| 2007-12-31 | CN¥747.13 Million ≈ $109.33 Million |
CN¥-9.83 Million ≈ $-1.44 Million |
-0.013x | -228.44% |
| 2006-12-31 | CN¥702.59 Million ≈ $102.81 Million |
CN¥-2.82 Million ≈ $-411.98K |
-0.004x | +54.64% |
| 2005-12-31 | CN¥781.05 Million ≈ $114.29 Million |
CN¥-6.90 Million ≈ $-1.01 Million |
-0.009x | -109.93% |
| 2004-12-31 | CN¥881.06 Million ≈ $128.93 Million |
CN¥78.36 Million ≈ $11.47 Million |
0.089x | -0.45% |
| 2003-12-31 | CN¥869.84 Million ≈ $127.28 Million |
CN¥77.72 Million ≈ $11.37 Million |
0.089x | +32.72% |
| 2002-12-31 | CN¥850.75 Million ≈ $124.49 Million |
CN¥57.27 Million ≈ $8.38 Million |
0.067x | -30.49% |
| 2001-12-31 | CN¥829.75 Million ≈ $121.42 Million |
CN¥80.36 Million ≈ $11.76 Million |
0.097x | -20.01% |
| 2000-12-31 | CN¥789.96 Million ≈ $115.60 Million |
CN¥95.64 Million ≈ $14.00 Million |
0.121x | -2.80% |
| 1999-12-31 | CN¥480.99 Million ≈ $70.38 Million |
CN¥59.91 Million ≈ $8.77 Million |
0.125x | -2.69% |
| 1998-12-31 | CN¥401.15 Million ≈ $58.70 Million |
CN¥51.35 Million ≈ $7.51 Million |
0.128x | -- |
About Ginwa Enterprise Group Inc
Ginwa Enterprise (Group) Inc. researches, develops, produces, markets, and sells traditional Chinese medicines, biological drugs, and chemical drugs primarily in China. The company offers a range of orthopaedics, immunity, children, and general medicines in various dosage forms, including tablets, capsules, granules, powders, mixtures, oral solutions, syrups, and external solutions. It is also in… Read more